KRMD
KORU Medical Systems, Inc. (KRMD) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
KRMD’s low debt-to-equity ratio supports a lighter capital footprint than many healthcare peers, but the provided data do not show direct emissions or resource-intensity advantages.
R&D spending at roughly 9.9% of revenue indicates continued product-development investment, which can support longer-term process efficiency versus peers with weaker innovation intensity.
The absence of disclosed environmental metrics in the supplied data limits evidence of superior waste, energy, or supply-chain stewardship relative to peers.
No post-August 2025 environmental disclosures were provided, so the assessment relies on limited metrics and cannot confirm a structural environmental edge.
Social
R&D intensity near 10% of revenue suggests ongoing investment in product quality and clinical relevance, which can support patient-focused outcomes versus less innovative peers.
Stock-based compensation at about 4.7% of revenue is moderate, implying some alignment of employee incentives without indicating unusually aggressive dilution versus peers.
The supplied data do not include workforce, safety, access, or customer-impact disclosures, limiting visibility into social performance relative to medtech peers.
Without controversy or incident data, KRMD appears neither clearly advantaged nor disadvantaged on social factors compared with peers.
Governance
Debt-to-equity of 0.18 indicates restrained leverage, which reduces balance-sheet pressure and supports governance discipline versus more levered peers.
Stock-based compensation at 4.7% of revenue is manageable, suggesting compensation practices that are less likely to be viewed as excessive than at many growth-stage peers.
Net debt to EBITDA near 5.0 is elevated relative to the low debt-to-equity figure, but the provided data do not indicate a severe governance weakness.
No filing-based evidence of control failures, board issues, or misconduct was provided, so governance positioning appears modestly stronger than average.
Overall Score
KRMD’s ESG profile is moderately positioned versus peers, with governance and social support from disciplined capital structure and R&D intensity, while environmental evidence remains limited.
Score Driver: Governance Discipline From Low Leverage And Moderate Compensation Intensity Relative To Peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on KORU Medical Systems, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.